Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04385277
Title Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Children's Oncology Group


nodular ganglioneuroblastoma


Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide

Age Groups: adult | child
Covered Countries USA | CAN

No variant requirements are available.